Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

By Markman M.   Kennedy A.   Sutton G.   Hurteau J.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 2, 1998-08 ,pp. : 272-274

Elsevier

Access to resources Recommend Favorite

Phase 2 Trial of Moderately High Dose Single Agent Mitoxantrone in Platinum and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Lichtman S.M.   Homesley H.   Kennedy A.   Webster K.   Ernst S.   Omura G.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 1, 1998-07 ,pp. : 123-126

Elsevier

Access to resources Recommend Favorite

Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum

By Markman M.   Zanotti K.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 91, Iss. 3, 2003-12 ,pp. : 573-576

Elsevier

Access to resources Recommend Favorite

Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients

By Safra Tamar   Ron Ilan   Boaz Mona   Brenner Joseph   Grisaru Dan   Inbar Moshe   Hayat Henry   Menczer Joseph   Golan Abraham   Levy Tally  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 463-468

Informa Healthcare

Access to resources Recommend Favorite

Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Kennedy A.   Webster K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 116-119

Elsevier

Access to resources Recommend Favorite